Dr Nick Camp
Linked
Drug Discovery
Consultancy
Providing a confidential and flexible service specialising in:
-
Medicinal Chemistry
-
Small Molecule Optimisation
-
Pre-Clinical Drug Discovery
-
Outsourcing
-
Due Dilligence
-
Disruptive Technologies
Supporting Clients Across The World.
Medicinal Chemistry
Defining Your Strategy
The goal of every medicinal chemist and drug discovery team is to deliver a molecule that is competent enough to test out a clinical hypothesis in humans. Whilst there is never a guarantee of success, having a well defined medicinal chemistry strategy is a critical component of any successful drug discovery effort. At the early stages, the selection of chemical starting points often determines the probability of failure or success. Using an issue-driven SAR strategy will help transform your Hits into quality Leads. During the optimisation phase and arguably earlier, teams should be focussed upon finding molecules which are optimal for testing in people. If you need assistance with any area of medicinal chemistry strategy, please contact Nick.
Drug Discovery Outsourcing
CRO Selection
Due to the high costs and unpredictable nature of drug discovery, biotech and start-up companies often look to outsource some or all of their research activities. Contract Research Organisations (CROs) provide flexible access to a range of services from individual FFS requests through to fully integrated programs. There are now many companies across Europe, Asia and the US and so finding the best fit for your research activities and budget is not always easy. Having worked both as a client and a project manager for a world leading CRO, Nick is uniquely positioned to help in your selection process, please contact him.
Disruptive Technologies
Innovation is Key To Success
There has never been more pressure upon the drug discovery industry. Patients need new and improved medicines and we need more cost effective and efficient ways to deliver them. Tackling disease by employing new modalities and technologies continue to be disruptive. AI and machine learning offers ways to identify biological targets and networks with better connectivity to disease. Computational tools such as virtual screening have the potential to identify novel candidate molecules in silico and significantly reduce the time and cost of medicinal chemistry in the laboratory. These technologies coupled with automated synthesis offer a complimentary approach to the industry. If you would like to discuss opportunities to explore such disruptive technologies, please contact Nick.
About Nick
Dr Nick Camp is a medicinal chemist with 28 years drug discovery experience gained within major pharma, biotech and CROs. He is a highly motivated drug hunter and co-inventor of several clinical candidates. During his project management role at WuXi AppTec, Nick worked with multiple clients across a range of therapeutic areas and modalities. As a group leader at Eli Lilly he drove the diversification of the UK chemistry group resulting in a significant increase in portfolio deliverables for the department, including multiple clinical candidates. During his time in biotech, Nick was involved in a successful collaboration that delivered the Factor Xa clinical compound LY517717 involving one of the earliest fragment based design approaches. He has extensive project leadership experience having worked across all phases of pre-clinical drug discovery and is recognised for developing future leaders. Nick helped to enhance links between Academia and Pharma through his role as Entrepreneur in Residence at the University of Southampton. He has a good track record of publications including, 15 scientific publications and 15 patents.
Expertise: Small Molecule Drug Discovery, Medicinal Chemistry Strategies, Design and SAR, Project Leadership, Project Management, Enzyme inhibitors, SBDD, FBDD, Issue-driven and Multi-dimensional SARs, Virtual Libraries, Disruptive Technologies, Lead Optimisation, Hit to Lead, Early Portfolio, Target Validation, Neuroscience.